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Abstract
Background: Understanding the biochemical mechanisms contributing to melanoma development and progression is
critical for therapeutical intervention. LKB1 is a multi-task Ser/Thr kinase that phosphorylates AMPK controlling cell growth
and apoptosis under metabolic stress conditions. Additionally, LKB1
Ser428 becomes phosphorylated in a RAS-Erk1/2-p90
RSK
pathway dependent manner. However, the connection between the RAS pathway and LKB1 is mostly unknown.
Methodology/Principal Findings: Using the UV induced HGF transgenic mouse melanoma model to investigate the
interplay among HGF signaling, RAS pathway and PI3K pathway in melanoma, we identified LKB1 as a protein directly
modified by HGF induced signaling. A variety of molecular techniques and tissue culture revealed that LKB1
Ser428 (Ser431 in
the mouse) is constitutively phosphorylated in BRAF
V600E mutant melanoma cell lines and spontaneous mouse tumors with
high RAS pathway activity. Interestingly, BRAF
V600E mutant melanoma cells showed a very limited response to metabolic
stress mediated by the LKB1-AMPK-mTOR pathway. Here we show for the first time that RAS pathway activation including
BRAF
V600E mutation promotes the uncoupling of AMPK from LKB1 by a mechanism that appears to be independent of
LKB1
Ser428 phosphorylation. Notably, the inhibition of the RAS pathway in BRAF
V600E mutant melanoma cells recovered the
complex formation and rescued the LKB1-AMPKa metabolic stress-induced response, increasing apoptosis in cooperation
with the pro-apoptotic proteins Bad and Bim, and the down-regulation of Mcl-1.
Conclusions/Significance: These data demonstrate that growth factor treatment and in particular oncogenic BRAF
V600E
induces the uncoupling of LKB1-AMPKa complexes providing at the same time a possible mechanism in cell proliferation
that engages cell growth and cell division in response to mitogenic stimuli and resistance to low energy conditions in tumor
cells. Importantly, this mechanism reveals a new level for therapeutical intervention particularly relevant in tumors
harboring a deregulated RAS-Erk1/2 pathway.
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Introduction
Melanoma is the most lethal human skin cancer and its
incidence is rapidly rising world-wide [1]. The development of
effective therapeutics designed to target melanoma requires a
comprehensive understanding of the underlying biochemical and
genetic processes contributing to melanocytic neoplasic transfor-
mation and the subsequent progression to an advanced melanoma
disease stage. Therefore, dissecting the aberrant signaling
pathways that are critical to melanomagenesis and understanding
the mechanisms by which these pathways interact with each other
has become the recent focus of research directed at melanoma
therapeutic intervention.
Dysfunctional receptor tyrosine kinase (RTK) signaling, in
particular through the hepatocyte growth factor (HGF) tyrosine
kinase receptor c-Met signaling pathway, is one important
hallmark of melanoma. HGF signaling activates Ras-Erk1/2 and
PI3K-AKT pathways, and Ras pathway activation has been
shown to play a role in melanoma development and maintenance
[2]. Notably, BRAF, a downstream activator in the RAS pathway
is mutated in nearly 70% of human melanoma (BRAF
V600E
activating mutation) while NRAS activating mutations occurs in
30% of melanomas (NRAS
Q61L activating mutation) [3]. In
addition, support for PI3K-AKT pathway signaling dysfunction in
melanomagenesis has been demonstrated by the documented loss
of the tumor suppressor PTEN-containing chromosomal region in
5–20% of melanomas as well as the over expression of AKT3 in
the advanced stages of this disease [4,5]. Strikingly, however,
single mutations within these two pathways are not sufficient to
promote melanoma development suggesting that a complex
interplay of these aberrant signalling pathways, under poorly
understood circumstances, promote melanomagenesis [2].
PLoS ONE | www.plosone.org 1 March 2009 | Volume 4 | Issue 3 | e4771We chose to investigate the potential interplay among the HGF
RTK signaling, the RAS Ras-Erk1/2 and the PI3K-AKT
pathways using the HGF transgenic mouse model in which
HGF is over-expressed and which develops melanoma in response
to neonatal ultraviolet (UV) radiation. This model is unique in that
it develops melanocytic neoplasms in stages that are highly
reminiscent of the human cutaneous malignant melanoma with
respect to biological, genetic and etiologic criteria [6,7].
To begin the analysis, we first searched for possible molecular
candidates with potential to mediate the HGF complex signaling
and identified the multitasking serine/threonine kinase, LKB1 [8]
as one candidate. LKB1 is involved in cell cycle control [9,10],
cellular energy metabolism [11] and cell polarity [12]. The cellular
localization and activity of LKB1 is controlled through its
interaction with the STE20-related adaptor (STRAD) and the
armadillo repeat-containing mouse protein 25 (Mo25); [13,14].
These finding led to the discovery that LKB1 is the upstream kinase
to AMP-activated protein kinase (AMPK) and is linked to mTOR
through the AMPK-TSC1/TSC2 cascade [15,16,17]. LKB1 is
phosphorylated on at least 8 residues, and evidence suggests that
LKB1 auto-phosphorylates itself on at least four of these, whereas
the other four are phosphorylated by upstream kinases [8]. Recent
studies show that human LKB1
Ser428 (the equivalent mouse residue
is LKB
Ser431) is phosphorylated in response to mitogenic signals
including EGF, TPA, elevated levels of cAMP as well as by PKCf
[18,19,20,21,22], where the EGF-mediated phosphorylation of
LKB1
Ser428 is dependent on the activation of p90
RSK. Although
experiments conducted in G361 melanoma cells indicate that this
residue is involved in LKB1-mediated cell growth inhibition [8,23],
and several other investigations implicate LKB1
Ser431 residue in the
activation of AMPK and BRK1/BRSK2 kinases (SAD-B/SAD-A)
[21,24,25], a recent publication stating that LKB1 phosphorylation
inthe C-terminal isnotrequired forregulationofAMPKBRSK1/2
and cell cycle arrest contradicts the previous findings [26].
Importantly, sporadic mutations in the lkb1 gene have been
documented in cancers of the breast, pancreas, lung, prostate,
cervical and ovary as well as in Peutz-Jeghers syndrome, a rare
disorder characterized by the appearance of intestinal polyps and
mucocutaneous melanocytic macules [27,28,29,30,31]. In Peutz-
Jegher patients, LKB1 may function as a tumor suppressor and is
associated with loss of heterozygosity or somatic mutation at the
lkb1 locus (for review [8]). More importantly, lkb1 mutations have
been described in melanoma [32] and based on this information
we determined if LKB1 could function as a potential link between
an activated RAS pathway and dysfunctional c-Met signaling and
play a role in melanoma development and progression.
In this study, we identify the mouse LKB1
Ser431 residue as a
phosphorylation target, not only for EGF, but also for HGF
signaling and demonstrate that this LKB1 phosphorylation is
executed in an Erk1/2-p90
Rsk-dependent manner, as previously
described in response to EGF stimulation [18,19]. We demon-
strate that LKB1
Ser428 residue is constitutively phosphorylated in
cells harboring BRAF
V600E activating mutations, and is found
frequently phosphorylated in mouse tumor samples with an
increased receptor tyrosine kinase activity suggesting a functional
connection between BRAF oncogenic pathway and LKB1.
Interestingly, BRAF
V600E mutant cells show a very limited
response to metabolic stress that appears to be mediated by
mechanism that involves the uncoupling of the energy stress sensor
pathway LKB1-AMPK-mTOR. Importantly, inhibition of RAS-
Erk1/2 pathway in BRAF
V600E mutant melanoma cell lines
restores the LKB1-AMPK-mTOR pathway response to metabolic
stress promoting apoptosis in coordination with the BH3-family
proteins Bad and Bim and the Bcl-2 family member Mcl-1.
Results
HGF induces LKB1
Ser428 phosphorylation in a RAS-Erk1/2-
p90
RSK pathway-dependent manner
We proposed to identify novel molecules involved in melanoma
development and progression analyzing the HGF specific signaling
in the UV induced HGF transgenic melanoma mouse model. To
understand the HGF specific signaling contributions we used 37-
31E-mouse melanoma cell line isolated from neoplasic lesions
raised in the HGF transgenic-UV irradiated mice and performed a
proteomic screening of the phospho-protein complexes induced
after the growth factor treatment (data not shown). As a result, we
identified LKB1 as a kinase that becomes phosphorylated in
response to HGF. Since previous studies implicates RAS pathway
in the modification of this residue we decided to use different cell
lines harboring either, BRAF wild type (37-31E, 37-31T, B16F1
and MeWo) or BRAF
V600E mutant cell lines (UACC903, A375
and SKMel28). As shown in Figure 1A, in isolated phospho-
protein complexes from 37-31E cells, LKB1
Ser431 was specifically
phosphorylated in response to HGF treatment since this
phosphorylation was totally prevented by the pretreatment with
the specific c-Met inhibitor PHA. LKB1
Ser428 (Ser431 in mouse) is
phosphorylated in response to EGF through RAS-Erk1/2-p90
RSK
pathway [18,20]. Since HGF triggering activates RAS and PI3K
pathway [33,34,35], we used specific Mek1/2 (U0126) and PI3K
(LY294002) inhibitors to determine which pathway was involved
in the LKB1
Ser431 phosphorylation. Figure 1B shows that in mouse
and human melanoma cells, HGF-induced phosphorylation of
LKB1
Ser431 was totally abolished by the specific Mek1/2 inhibitor
U0126, whereas the PI3K inhibitor LY294002 had no effect on
HGF-induced phosphorylation of LKB1
Ser431. Furthermore, time
course experiments showed that p90
RSK became phosphorylated
in response to HGF and its phosphorylation profile correlated with
LKB1
Ser431 phosphorylation (Fig. 1C). Additionally, analysis of
B16F1 melanoma cells showed that the phosphorylation of the
LKB1
Ser431 was p-Erk1/2 dependent (Fig. 1C) and, inhibition of
Mek1/2 after HGF treatment in 37-31E cells totally abolished the
phosphorylation of Erk1/2, p90
RSK and LKB1
Ser431 (Fig. 1C). To
confirm the p90
RSK participation we used the p90
RSK specific
inhibitor BI-D1870. Treatment of 37-31E cells with BI-D1870
abolished the HGF-mediated phosphorylation of LKB1
Ser431
(Fig. 1D). The observed activation upon BI-D1870 treatment of
Erk1/2 and the increased levels of p-CREB
Ser133 is in agreement
with the suggested p90
RSK negative-feedback loop that regulates
Erk1/2 described by other authors [20].
These results show that, LKB1
Ser428 is phosphorylated in




Ser428 is phosphorylated in response to different
growth factors and is highly phosphorylated in
melanoma cells harboring BRAF
V600E mutations and in
tumor samples
Next, we investigated if this post-translational modification was
broader in scope. We tested several growth factors related to
cancer development in human and mouse melanoma cell lines to
check whether or not these ligands were able to induce LKB1
Ser428
phosphorylation. As suggested by previous investigations [18], all
ligands tested, including HGF, EGF, basic fibroblast growth factor
(FGF2), insulin like growth factor 1 (IGF-1), platelet derived
growth factor (PDGF), tumor necrosis factor-alpha (TNF-a),
herregulin, insulin and phorbol-ester tumor promoter TPA were
able to induced LKB1
Ser428 phosphorylation in a cell type
RAS Pathway and LKB1
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Erk1/2 and p90
RSK kinases led to the phosphorylation of
LKB1
Ser428 (Fig. 2A).
The aberrant regulation of the Ras-Erk1/2 pathway represents
one of the hallmarks in cancer. Considering that 70% of human
melanomas harbor BRAF activating mutations [3], we determined
the phosphorylation status of LKB1
Ser428 in different human
melanoma cell lines harboring BRAF
V600E activating mutations in
serum free and complete medium conditions. As expected,
SKMel28, A375, and UACC903 human melanoma cell lines
harboring the BRAF
V600E mutation demonstrated a constitutively
phosphorylated LKB1
Ser428 residue whereas the MeWo human
melanoma cell line that harbors the wild type alleles did not
(Fig. 2B).
Based on the above results, tumor samples with a deregulated
tyrosine kinase pathway and/or with enhanced RAS-mediated
Figure 1. HGF induces LKB1
Ser431 phosphorylation in a RAS-p90
RSK dependent manner. (A) Five mg of phospho-protein isolated
complexesfrom samples: untreated(Control),HGF triggered(40 ng/ml) w/o PHA(0,2 mM) were resolved by SDS-PAGE. p-LKB1
Ser428, p-Erk1/2
Thr202/Tyr204
and Erk2 antibodies were probed against the membrane. Ponceau S staining of membrane is showed for phospho-protein extracts loading
control. (B) 37-31E, 37-31T, SKMel28, and MeWo cells were treated in serum starvation conditions with HGF (40 ng/ml), U0126 (10 mM) and
LY294002 (10 mM) as indicated in the figure. Western-blots show the levels of the indicated proteins. (C) Time course showing the
phosphorylation of the LKB1
Ser431 and p-90
RSK Thr359/Ser363 after HGF triggering (40 ng/ml) under serum starvation conditions. LKB1 total
protein is shown as a loading control. On the right, LKB1
Ser431 is phosphorylated in response to HGF in an Erk1/2-p90
RSK dependent manner.
Time course shows the phosphorylation of Erk1/2
Thr202/Tyr204 and LKB1
Ser428 in B16F1 cells. Down below, 37-31E melanoma cells were serum
starved and triggered with HGF (40 ng/ml) for 5 minutes. Then, cells were treated with the Mek1/2 specific inhibitor U0126 (10 mM) for the
indicated increasing times. Fifty mg of total lysates were resolved by SDS-PAGE and membrane was probed with the indicated antibodies.
(D) 37-31E cells were treated for 10 min in serum starvation with HGF (40 ng/ml) in the presence or absence of U0126 (10 mM) or BI-D1870
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LKB1
Ser428 phosphorylation. In this matter, the phosphorylation
state of LKB1
Ser431 in spontaneous tumor samples raised in UV-
irradiated HGF transgenic mice and in xenographed tumors from
the 37-31E-melanoma cells correlated with elevated levels of p-
Erk1/2 (Fig. 2C).
All together, these data indicated the existence of a RAS
pathway and LKB1 crosstalk suggesting that LKB1 might be
involved in some of the RAS-Erk1/2 induced-responses, and more
importantly would be contributing to BRAF oncogenic signaling.
BRAF mutant melanoma cells have a dysfunctional LKB1-
AMPK energy stress-induced pathway response
Melanoma cells are especially resistant to different types of
stress. LKB1 is the AMPKa upstream kinase that becomes
phosphorylated in response to metabolic stress controlling protein
synthesis through mTOR pathway. Considering the LKB1
Ser428
phosphorylation as a read out of the RAS and LKB1 pathways
interaction, the constitutive phosphorylation of LKB1
Ser428 in
BRAF mutant cells suggested a possible interplay between LKB1-
AMPK pathway and BRAF oncogenic signaling. Therefore, we
investigated the LKB1-AMPK pathway activation in three
different BRAF
V600E mutant melanoma cell lines under low
energy conditions and the contribution of BRAF
V600E signaling to
the energy sensor pathway. To test this hypothesis we starved
BRAF mutant melanoma cells under serum free and low glucose
conditions in the presence or absence of the Mek1/2 inhibitor
U0126, and investigated the activation of LKB1-AMPK-mTOR
pathway. UACC903, SKMel28 and A375 cells showed a very
limited response to energy withdrawal as measured by the
induction of phospho-AMPKa (Fig. 3A). Under these conditions
all cells retained considerable mTOR activity as indicated by the
phosphorylation levels of ribosomal protein S6 (Fig. 3A). However,
the addition of U0126 (10 mM) recovered AMPKa pathway
Figure 2. LKB1
Ser431 (Ser428 human) is phosphorylated in response to different growth factors, in BRAF
V600E mutant melanoma
cells and mouse tumor samples. (A) B16F1, 37-31T and MeWo cells were serum starved and treated with HGF (40 ng/ml), EGF (100 ng/ml), FGF2
(100 ng/ml), Herregulin (50 ng/ml), IGF-1 (50 ng/ml), PDGF (50 ng/ml), TNF-a (100 ng/ml) Insulin (100 nM) and TPA (200 nM). Fifty mg of total lysates
were separated by SDS-PAGE and same membranes were incubated against the indicated antibodies. (B) MeWo (BRAF wild type), A375 (BRAF
V600E),
SKMel28 (BRAF
V600E) and UACC903 (BRAF
V600E) human melanoma cells were growth in complete medium (CM) or serum starvation (SF) conditions as




is shown. Total Erk1/2 is used as a loading control. Cell genotypes are showed. (C) p-LKB1
Ser431 and p-Erk1/2
Thr202/Tyr204 levels in mouse melanoma
tumor samples. Samples 1–7 primary tumors raised in HGF-UV irradiated transgenic mice. Samples 8 and 9 show xenograph tumors generated from
37-31E cells in FVB mice with high and low p-Erk1/2 levels, respectively. As a control fifty micrograms of protein from 37-31E melanoma cell line
treated with HGF (40 ng/ml) for 10 minutes was added (Total lysates, T.L.). Same membrane was blotted against the indicated antibodies.
Quantifications of phospho-proteins normalized against total protein are showed in the graphs below.
doi:10.1371/journal.pone.0004771.g002
RAS Pathway and LKB1
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complete abrogation of mTOR activity as indicated by phospho-
S6 ribosomal protein (Fig. 3A). In contrast, 37-31E melanoma cells
harboring wild type BRAF did not show this effect by the addition
of U0126 under low energy conditions (Fig. 3A). Interestingly, the
re-activation of the AMPKa pathway in BRAF mutant cells
correlated with the total inactivation of Erk1/2 and the unpho-
sphorylated LKB1
S428 (Fig. 3A). Importantly, the addition of
U0126 up to 10 mM in serum free high glucose conditions did not
induce the activation of AMPKa [36] (Fig. 3B). To confirm the
reconnection of the AMPK pathway after inhibition of oncogenic
BRAF signaling we used AICAR (5-Aminoimidazole-4-carbox-
yamide ribonucleoside) instead of low glucose in order to stimulate
the activation of the AMPK pathway. As expected, the addition of
AICAR, which increases AMPK phosphorylation levels by a
mechanism that appears to be due to the inhibition of AMPK
dephosphorylation [37,38,39], slightly increased the p-AMPK
levels in serum starvation. The addition of U0126 inhibitor
resulted in a clear increment the p-AMPKa levels (Fig. 3C). Since
this effect was observed in BRAF
V600E mutant cells, we repeated
the experiments using the BRAF inhibitor sorafenib. Notably,
inhibition of BRAF
V600E signaling with sorafenib recovered the
activation of AMPK pathway in response to metabolic stress.
Interestingly, sorafenib treatment under low glucose condition
reduced Erk2 protein levels by a currently unknown mechanism
(Fig. 3D). Importantly, experiments knocking–down BRAF
V600E
performed in serum free and low glucose medium also resulted in
an increased of p-AMPKa levels (Fig 3D).
In addition, we tested whether p90
RSK signaling was mediating
the observed effect using the p90RSK specific inhibitor BI-D1870.
Experiments were done in the presence of EGF to assured the
activation of RAS pathway. Treatment of cells with the p90
RSK
inhibitor BI-D1830 did not recover the cells response to low energy
conditions as indicated by the p-AMPK levels (Fig. 3E) suggesting,
that the oncogenic BRAF-mediated LKB1
Ser428 phosphorylation
was not sufficient to account for the observed response. As
Figure 3. Inhibition of oncogenic BRAF
V600E signaling restores the limited response to metabolic stress of BRAF mutant melanoma
cell lines. (A) BRAF mutant melanoma cells have a limited response to energy withdrawal that is restored by U0126 treatment. Fifty micrograms of
total lysates from UACC903, A375, SKMel28 and 37-31E melanoma cells grown in serum free high glucose medium (H.G.), serum free low glucose
medium (L.G.) or serum free low glucose medium (L.G.) plus 10 mM of U0126 for 4 hours were separated by SDS-PAGE. Western-Blot shows the
activation status of proteins in the RAS and LKB1-AMPK-mTOR pathways. (B) U0126 inhibitor treatment does not activate AMPK. UACC903 A375 and
SKMel28 melanoma cells were grown in high glucose medium with serum in the absence or presence of 1 mM, 5 mMo r1 0mM of U0126. Total protein
lysates were subjected to SDS-PAGE. Western-blot shows the phosphorylation state of AMPKa in the presence of different concentrations of U0126.
(C) Inhibition of BRAF signaling increases cell response to AICAR. UACC903 and SKMel28 cells were grown in complete medium; cells were treated





were checked by western blot. (D) Sorafenib treatment and siRNA BRAF knockdown restores the metabolic stress pathway in BRAF mutant
melanoma cells. In the left panel, UACC903, A375 and SKMel28 melanoma cells were grown in low glucose serum free medium+/2EGF (50 ng/ml) for





proteins under the different conditions. In the right panel SKMel28 cells were transfected with either a scramble siRNA or BRAF siRNA. 72 hours after
transfection, cells were starved either in high glucose (H.G.) or low glucose (L.G.) medium for six hours. Western-blots show the levels of p-AMPKa
T172,
p-Erk1/2
Thr202/Tyr204 and BRAF proteins. (E) p90
Rsk inhibitor BI-D1870 (10 mM), does not restore the metabolic stress pathway. UACC903, A375 and
SKMel28 melanoma cells were grown in low glucose serum free medium+/2EGF (50 ng/ml) for 4 h in the presence or absence of BI-D1870 (10 mM).
Western blots show the levels of the indicated proteins under the different conditions.
doi:10.1371/journal.pone.0004771.g003
RAS Pathway and LKB1
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CREB
Ser133 phosphorylation mediated by the suggested p90
RSK
negative-feedback loop that regulates Erk1/2 [20].
Altogether these data show evidences that indicate that
melanoma cells harboring oncogenic BRAF have a diminished
response to metabolic stress. Importantly, the inhibition of the
oncogenic BRAF signaling, that connects RAS pathway to LKB1,
restored the AMPK-mediated energy stress sensor pathway.
However the results also indicate that the inhibition of the
LKB1
Ser428 phosphorylation is not enough to recover the pathway
LKB1-AMPK-mTOR response, suggesting the existence of
additional mechanisms.
Growth factor treatment and oncogenic BRAF
V600E
induce LKB1-AMPK disassembly
The LKB1 tumor suppressor kinase activity is not related to its
phosphorylation state [14]. Thus, its contribution to the different
biological processes is likely to be mediated by its interaction with
other proteins and/or its cellular localization. LKB1 controls
protein synthesis and cell growth through the AMPK-TSC1/
TSC2 cascade [15,16,17]. Mitogenic responses coordinate simul-
taneously cell growth with cell division. Since the activation of
AMPK-TSC1/TSC2 pathway by LKB1 controls energy metab-
olism and protein synthesis, we examined whether the growth
factor treatment leads to LKB1-AMPK dissociation, providing a
mechanism that would assure cell growth upon a mitogenic
stimulus and resistance to energy stress conditions. To investigate
the underlying mechanism, we transfected 293T cells with Flag-
tagged LKB1 and GST-AMPKa and then treated the cells with or
without EGF in order to activate RAS pathway. After immuno-
precipitation of the Flag-LKB1 complexes we checked for the
presence of GST-AMPKa in the immunocomplexes. The data
indicated that some fraction of AMPKa is constitutively bound to
LKB1. Interestingly, treatment of cells with the growth factor
induced dissociation of the LKB1-AMPKa complexes (Fig. 4A).
Moreover, this effect was totally independent of LKB1 kinase
activity since Flag-tagged kinase dead LKB1 (LKB1
KD) repro-
duced exactly the same result. Since growth factor stimulation
promoted LKB1-AMPKa disassembly and this effect correlated
with the phosphorylation of LKB1
Ser428 upon growth factor
stimulation, we examined the role of the Ser428 (Ser431 in mouse)




S431D phospho-mimetic mutant and
the LKB1
KD constructs together with GST-AMPKa in 293T cells
and repeated the previous experiment. Again when LKB1
WT and
LKB1
KD were transfected the EGF treatment promoted the
disassembly of the LKB1-AMPKa complex. However, GST-
AMPKa did not form a complex with either the LKB1
S431A or
LKB1
S431D mutants, suggesting that, in response to growth factors,
the Ser428 residue would be involved in the binding or stability of
the LKB1-AMPKa complexes (Fig. 4B).
The above data suggested that the limited response to metabolic
stress of BRAF mutant melanoma cells could be caused by the
dissociation of LKB1-AMPKa complexes. Thus, the inhibition of
BRAF signaling by U0126 inhibitor would permit the reconnec-
tion of the pathway. To confirm that, we performed an
immunoprecipitation of the endogenous LKB1 in the BRAF
mutant melanoma cells and examined the AMPKa association
under low energy conditions with or without U0126 inhibitor.
UACC903 and A375 melanoma cells showed an increase in the
number of AMPKa molecules associated to LKB1 when BRAF
signaling pathway was blocked (Fig. 4C). This re-assembly was also
associated with an increase in AMPKa
T172 phosphorylation levels.
Similar results were obtained when endogenous p-AMPKa
T172
was immunoprecipitated from SKMel28 melanoma cells under
same conditions, confirming the suggested mechanism (Fig. 4C).
Additionally, we reconstitute the system in Hela cells that do not
express endogenous LKB1. Hela cells were transfected with Flag-
LKB1 and GST-AMPKa in the presence or absence of oncogenic
myc-BRAF
V600E under low glucose conditions. The expression of
oncogenic BRAF
V600E induced the complex dissociation that was
totally rescued by the addition of U0126 inhibitor (Fig. 4D).
These data showed evidences that support the growth factor
treatment and RAS pathway activation mediated disassembly of
the LKB1-AMPK complexes. Importantly the inhibition of the
RAS pathway in cells harboring BRAF
V600E mutation restores the
LKB1-AMPKa pathway by permitting the re-association of the
LKB1-AMPKa complexes. Furthermore, these data also suggest-
ed that although growth factor stimulation induces LKB1
Ser428
phosphorylation, additional mechanisms should be involved
promoting the RAS pathway-dependent LKB1-AMPK disassem-
bly.
Restoration of the LKB1-AMPKa pathway in BRAF
V600E
melanoma cells under energy stress conditions induces
apoptosis in coordination with Bad, Bim and Mcl-1
Next, investigated the cell survival response of BRAF
V600E
mutant melanoma cell lines with a restored LKB1-AMPKa
pathway under stress energy conditions. According to the accepted
mechanism, elevation of intracellular AMP levels will activate
LKB1 that in turn activates AMPK and regulates apoptosis in
response to energy stress [16]. Additionally, it has been shown that
blocking BRAF signaling in BRAF
V600E mutant cell lines for long
periods of time (24–48 hours) promotes apoptosis through the
regulation of BH3-family proteins [40,41]. We subjected
UACC903 and A375 melanoma cells to metabolic stress
conditions for a maximum of 12 hours in the presence or absence
of the Mek1/2 inhibitor. Then, we measured cell viability and
apoptosis by nuclear staining exclusion (Guava ViaCount) and
Annexin V and propidium iodide (PI) double staining. UACC903
and A375 melanoma cell lines showed some spontaneous
apoptosis under normal growing conditions: 5.71% and 3.27%
respectively. The addition of Mek1/2 inhibitor for 12 hours in
high glucose medium did not promote any increment in the
apoptosis rate (UACC903 5.38% and A375 2.70%). Glucose
starvation for 12 hours resulted in slight increase in the number of
double positive Annexin V-PI cells respect normal growing
conditions: 1.27 fold for UACC903 cells and 2.35 fold for A375
cells. However, the restoration of the LKB1-AMPKa pathway by
inhibition of Mek1/2 under low glucose conditions resulted in a
considerable number of apoptotic cells (5.7 and 6.4 fold increase
respectively); (Fig 5A). Similar results were observed when viable
cells were analyzed by PI exclusion (Fig. 5A). The results were
correlated with the molecular status of the pathways implicated in
a time course fashion. As shown before, the inhibition of Erk1/2
phosphorylation resulted in the decrease of phopho-LKB1
Ser428
levels and the restoration of the LKB1-AMPKa pathway. In turn,
the LKB1-AMPKa pathway was able to sense the low energy
conditions as soon as 4 hours after glucose starvation, indicated by
the levels of p-AMPKa
T172 (Fig. 5B). Interestingly, the increase in
the number of apoptotic cells did not correlate with p53
stabilization. On the contrary, p53 levels were down-regulated
under these conditions in all cell lines, suggesting the participation
of BRAF signaling in the stabilization of p53 and a p53-
independent apoptotic mechanism (Fig. 5B).
In order to establish a causal link among the inhibition of BRAF
signaling, the AMPK pathway re-activation, and the increased
number of dead cells, we knocked-down AMPKa in UACC903
RAS Pathway and LKB1
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conditions to the inhibition of the oncogenic BRAF signaling. As
showed in figure 5C, blocking BRAF signal under low energy
conditions in control cells resulted in elevated levels of p-
AMPKa
T172 together with an increment in the number of dead
cells. However, AMPKa knock–down cells did not show any
increase in the number of dead cells under similar conditions.
As mentioned previously, BRAF suppresses apoptosis, targeting
the BH3-family of proteins in BRAF
V600E mutant cells [40]. In
high glucose medium the addition of the U0126 inhibitor for
12 hours caused a small decrease of p-Bad and the Bcl-2 family
member Mcl-1 protein levels together with a slight increase in the
amount of BimEL. Interestingly, when the LKB1-AMPKa
pathway was restored under low glucose conditions, the increased
number of dead cells correlated with a stronger biochemical
response including the complete de-phosphorylation of Bad, the
stabilization of the non-phosphorylated BimEL isoform and the
drastic down-regulation of Mcl-1 (Fig. 5D).
Our results indicated that in a BRAF mutant context, the
reactivation of LKB1-AMPK-mTOR pathway under low energy
conditions together with the inhibition of oncogenic BRAF
signaling for short periods of time, promoted a pronounced
apoptosis response through the de-phosphorylation of Bad,
stabilization of BimEL and the down-regulation of Mcl-1.
Figure 4. Growth factor treatment and BRAF
V600E promotes LKB1-AMPKa disassembly. (A) 293T cells were transiently transfected for 48 h
with Flag-LKB1, Flag-LKB1KD (kinase dead) and GST-AMPKa as indicated. Then, cells were treated with 100 ng/ml of EGF for 10 min.
Immunocomplexes pulled down with an anti-Flag-resin were separated by SDS-PAGE and proteins present in the complexes were analyzed by
western blot. Total lysates show the transfection controls and the response to growth factor treatment. (B) 293T cells were transiently transfected
with the constructs indicated. Then, cells were serum starved for 2 h and treated with 100 ng/ml of EGF for 10 min and protein complexes were
immunoprecipitated with anti-Flag-resin. Protein complexes were separated by SDS-PAGE. Levels of GST-AMPKa, Flag-LKB1 constructs and the
phosphorylation state of LKB1
Ser431 in the complexes are shown. Quantification of the amount of GST-AMPKa normalized to the Flag-LKB1
immunoprecipitated is represented in the graph. Total lysates are shown for control transfection of the different samples. (C) Endogenous LKB1 from
UACC903 and A375 melanoma cells growing in low glucose medium (L.G.) with or without 10 mM U0126 was immunoprecipitated. Western-blot from
the immunoprecipitated samples was probed against LKB1, AMPKa and p-AMPKa
T172 antibodies. On the right, total lysates from SKMel28 melanoma
cells growing in complete medium (High Glucose, H.G.) low glucose medium (L.G.) in the presence or absence of 10 mM U0126 were subjected to
immunoprecipitation with the anti-p-AMPKa
T172. Samples were separated by SDS-PAGE. Total lysates (T.L.) from low glucose plus U0126 treated cells
are showed as a control. Western-Blot of the immunoprecipitated samples was performed against total AMPKa antibody. (D) Hela cells were
transfected with Flag-LKB1, GST-AMPKa and myc-BRAF
V600E or and empty vector as indicated. Flag-LKB1 was immunoprecipitated and western-blots
from immunoprecipitated samples were probed against the indicated antibodies. Graph shows the quantification of the AMPK bound to LKB1.
doi:10.1371/journal.pone.0004771.g004
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The understanding of the molecular and biochemical mecha-
nisms contributing to melanoma development and progression is
critical for therapeutical intervention. The UV-induced HGF
mouse melanoma model recapitulates chronologically and histo-
pathologically all the stages of human melanoma [6,7]. We
investigated the potential interplay among the HGF RTK
signaling, the RAS-Erk1/2 and the PI3K-AKT pathways using
the HGF mouse model. In neoplasic melanoma cells isolated from
spontaneous tumors raised in the mouse model, we identified
LKB1 as one of the molecules responsive to HGF triggering. As
previously described for EGF [18], we show that HGF and several
other growth factors induce the phosphorylation of LKB1
Ser431
through the Ras-Erk1/2-p90
RSK pathway. Interestingly, this
residue appears to be constitutively phosphorylated in human
melanoma cells harboring BRAF
V600E activating mutation as an
indicator of the connection between RAS pathway and LKB1.
The role of LKB1 in response to growth factors, and its connection
to the RAS pathway, is mostly unknown. Our results show that
melanoma cells harboring the BRAF
V600E oncogenic mutation
have a very limited response to metabolic stress. Interestingly, the
inhibition of the BRAF signaling restores the ability of the cells to
sense the low energy conditions. Notably, growth factor treatment
and oncogenic BRAF
V600E leads to the uncoupling of LKB1-
AMPKa complexes, suggesting a mechanism that disconnects the
energy sensor pathway, which is involved in controlling cell growth
through the mTOR pathway in response to low energy conditions.
Figure 5. Restoration of the LKB1-AMPKa pathway in BRAF
V600E melanoma cells induces apoptosis under energy stress conditions.
(A) UACC903, A375 and SKMel28 human melanoma cells were grown in complete medium (H.G.), or low glucose medium (L.G.) with or without
10 mM of the Mek1/2 specific inhibitor U0126 for 12 h. Then, Annexin V and PI (propidium iodide) positive cells were analyzed by flow cytometry.
Histograms show the result from FACS analysis. Graphs on the right show the percentage of viable and dead cells in a parallel experiment under the
same conditions determined by nuclear staining exclusion (Guava-ViaCount). (B) Time course at 4 and 12 hours showing the LKB1-AMPKa pathway
status under the same conditions. UACC903, A375 and SKMel28 human melanoma cells were grown in complete medium (high glucose H.G.), low
glucose medium (L.G.) with or without 10 mM of the Mek1/2 specific inhibitor U0126 for the times indicated. Fifty micrograms of total protein lysates
were separated by SDS-PAGE and same membranes were blotted against the indicated antibodies. All experiments were done at least three times.
Representative experiments are shown. (C) UACC903 cells were transfected either with a scramble siRNA or with equimolar amounts of AMPKa1 and
AMPKa2 siRNAs for a total concentration of 100 nM. 72 hours after transfection cells were starved in low glucose medium for 6 hours in the presence
or absence of 10 mM of U0126. Dead cells were quantified by nuclear staining exclusion (Guava-ViaCount). Western-blots show the levels of p-
AMPKa
T172, AMPKa and p-Erk1/2
Thr202/Tyr204 under the different conditions. (D) UACC903 and A375 melanoma cells were grown in complete medium
(H.G. cm), serum free high glucose medium (H.G. sf), serum free low glucose medium (L.G.), serum free complete medium plus U0126 10 mM
(H.G.+U0126) and low glucose serum free medium plus U0126 10 mM (L.G.+U0126) for 12 hours. The levels of Bim, phospho-Bad and Mcl-1 are
showed under the different experimental conditions.
doi:10.1371/journal.pone.0004771.g005
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the association of the LKB1-AMPKa complexes and results in an
increase of apoptosis in response to metabolic stress.
Our screening for the discovery of novel molecules involved in
HGF signaling in melanoma cells allowed us to identify by DIGE
analysis proteins that were directly modified in response to c-Met
activation by HGF (data not shown). Previously, it has been
described that EGF and forskolin promote the phosphorylation of
LKB1
Ser428 in a p90
RSK and PKA dependent manner respectively
[18,19]. Our results showed that LKB1
Ser431 phosphorylation
occurs in response to HGF and other different growth factors in a
RAS-Erk1/2-p90
RSK dependent manner as initially suggested by
previous investigations [18,19]. Interestingly, and according to
siRNA knock down experiments (data not shown), cells expressing
less than five percent of the LKB1 pool still respond to this
stimulus, suggesting that LKB1 would have a relevant role in the
mitogenic response to growth factors. Virtually all cancers have
aberrant signaling of receptor tyrosine kinases (RTKs), growth
factors autocrine loops or activating mutations in the RAS
pathway (RAS activating mutations or BRAF
V600E mutation).
We therefore hypothesized that LKB1 would be mediating some
of the effects of the RAS and BRAF oncogenes. In agreement with
this, LKB1
Ser428 appears to be constitutively phosphorylated in
human melanoma cell lines harboring BRAF
V600E activating
mutations as an indicator of the interplay between RAS pathway
and LKB1. Furthermore, LKB1
Ser431 (Ser428 in human) tends to
be phosphorylated in mouse tumor samples harboring deregulated
tyrosine kinase activities or increased mitogenic signaling,
suggesting the direct participation of LKB1 in tumor biology.
LKB1 activity is controlled through its interaction with the
STE20-related adaptor (STRAD) and Mo25 [13,14]. LKB1 can
be phosphorylated at eight or more different residues, where the
modifications at these amino acids have no effect on LKB1 kinase
activity [8]. In the last five years a number of publications have
reported several critical roles for LKB1 in different biological
processes such as: energy metabolism [11,16], cell polarity and
division [12,11] and transcriptional regulation [10]. However,
most of these studies rely on the presence or absence of LKB1 in
these processes. Our data show that growth factor treatment
induces both, LKB1
Ser428 phosphorylation and the dissociation of
LKB1-AMPKa complexes. The participation of this residue in
growth inhibition, cell polarity and the activation of the LKB1
downstream kinases (AMPK, BRSK1/2) have been controversial
[8,21,23,25,26]. Indeed, our results regarding the participation of
this residue in the growth factor-mediated dissociation of the
LKB1-AMPKa complexes are not conclusive and more research is
needed in order to elucidate the complete role of this residue.
Moreover, we can no exclude the participation of additional
residues or proteins in the process.
LKB1 is the upstream kinase of AMPKa and is linked to
mTOR through the AMPK-TSC1/TSC2 cascade [15,16,17]
controlling cell growth under energy stress conditions. One
possible interpretation of our results would be that the dissociation
of the LKB1-AMPKa complex would provide a mechanism to
avoid interruption of protein synthesis through this pathway while
cells are responding to a mitogenic stimulus. In this matter, the
activation of RAS-Erk1/2 pathway would engage biochemical
mechanisms to coordinate cell growth and division to assure cell
proliferation. Importantly, the deregulation of the AMPK-mTOR
axis by the dissociation of the LKB1-AMPKa complex in cells
harboring RAS pathway activating mutations could represent an
advantage for proliferation and a significant resistance increased to
metabolic stress conditions. Notably, BRAF
V600E mutant melano-
ma cell lines showed a limited sensitivity in response to low energy
conditions. Treatment of cells with the Mek1/2 inhibitor U0126
allowed the formation of endogenous LKB1-AMPKa complexes
and restored the energy sensor pathway in response to low energy
conditions, supporting the proposed mechanism (Fig. 6). Mek1/2
inhibitors (U0126, PD98059) have been reported to activate
AMPK at 20 mM concentration, but not at 5–10 mM [36]. These
experiments were done in glucose free medium and in the
presence of growth factors with high levels of phospho-Erk1/2.
According to our data the inhibition of the Erk1/2 pathway under
low energy conditions would allow the re-association of LKB1-
AMPKa, which in turn would result in an increase the levels of p-
AMPKa. Furthermore, our data showed that in high glucose
medium the addition of U0126 (10 mM) or sorafenib (data not
shown) had no effect on AMPKa phosphorylation in all BRAF
mutant cell lines (Fig 5A). Up-to-date the connection between
RAS pathway and LKB1 has been limited to the phosphorylation
of LKB1
Ser428 residue through p90
RSK. However, our results
indicate that this modification is not enough to mediate the
observed effect, suggesting the existence of additional biochemical
mechanisms mediated by Erk1/2 that will account for the LKB1-
AMPKa dissociation mediated by the RAS pathway (Fig. 6).
The activation of AMPKa by LKB1 under energy stress,
stimulates glucose uptake and fatty acid oxidation to increase ATP
production, inhibits protein synthesis and protects cells from
undergoing apoptosis [8]. Surprisingly, the inhibition of Erk1/2
pathway in BRAF mutant melanoma cell lines subjected to
metabolic stress resulted in an increase in the number of dead cells
(Fig 6). Interestingly, our experiments knocking-down AMPKa
suggests a causal link among the inhibition of oncogenic BRAF
signaling, the reconstitution of the energy sensor pathway and the
resulting cell death. In agreement with the interplay between the
oncogenic signaling and AMPK is the recent finding where the
activation of AMPK pathway by administration of metformin,
phenformin or A-769662 to PTEN(+/2) mice significantly
delayed tumor onset, demonstrating that LKB1 is required for
activators of AMPK to inhibit mTORC1 signaling as well as cell
growth in PTEN-deficient cells [42]. Interestingly, the increased
apoptosis rate did not correlate with the stabilization of p53,
indicating that the mechanism was apparently p53-independent
and that BRAF oncogenic signaling was participating in the
stabilization of p53. In fact, it is known that under genotoxic-stress
conditions, Erk1/2 signaling mediates p53 stabilization [43,44].
Furthermore, the AMPK-induced p53 activation has been
reported to promote cell survival in response to glucose
deprivation in MEFs [45], while our data in BRAF mutated
melanoma cells clearly showed an increase in apoptosis.
Recent publications have shown that oncogenic BRAF can
suppress apoptosis through targeting BH3-only proteins Bad and
Bim [40,41]. Our results indicate that the inhibition of oncogenic
BRAF signaling at 12 h promotes a slight de-phosphorylation of
Bad and the stabilization of BimEL, most likely, by inhibiting its
Erk1/2-dependent phosphorylation and proteasome-mediated
degradation [46]. The reactivation of the LKB1-AMPK-mTOR
pathway under low energy conditions by the inhibition of BRAF
signaling led to a more pronounced effect that included a drastic
down-regulation of Mcl-1 (Fig 6). Interestingly, Mcl-1 has been
shown to be an important melanoma anti-apoptotic protein [47].
In conclusion, in this report we show that activation of RAS
pathway by growth factors and oncogenic BRAF
V600E results in
the dissociation of LKB1-AMPKa. These results, permit us to
speculate that under normal growth conditions, this biochemical
mechanism, through the activation of RAS pathway, could be
involved in the coordination of two important processes in cell
proliferation: cell growth and cell division. Interestingly,
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V600E mutant melanoma cells have minimal response to
energy stressed conditions due to the constitutive dissociation of
the LKB1-AMPKa complexes. However, under metabolic stress
conditions the inactivation of BRAF oncogenic signaling restores
the LKB1-AMPKa-mTOR pathway-promoting apoptosis in
collaboration with BH3-only proteins and Mcl-1 (Fig 6). Impor-
tantly, this mechanism reveals a new level for therapeutical
intervention triggering apoptosis of tumor cells. This might be
particularly relevant in tumors harboring a deregulated RAF-
Erk1/2 pathway that survive in energy stress conditions.
Materials and Methods
Cell lines
37-31E and 37-31T cells have been described previously [33].
The 293T, Hela, SKMel28, MeWo, A375 and B16F1 cell lines
were from ATCC. The 293T cells and Hela cells were maintained
in DMEM (Gibco) with 10% FBS and penicillin/streptomycin,
while the 37-31E and 37-31T cells were supplemented with EGF
(5 ng/ml) (Invitrogen) and Insulin (4 mg/ml) (Invitrogen). The
human melanoma cell lines SKMel28 and were grown in MEM
(ATCC) supplemented with 10% FBS plus penicillin/streptomycin
(Gibco). UACC903 were a gift from J. Trent (P. Pollock), Tgen
Phoenix, Arizona. All cell lines were growth under 37uC and 5%
CO2 conditions. For low glucose conditions cells were put in
DMEM (Gibco) or MEM (Gibco) low glucose medium plus
penicillin/streptomycin for at least 4 h.
Phospho-protein isolation
37-31E cells were serum starved for two hours and then
triggered with 40 ng/ml of HGF (R&D) for 10 minutes in the
presence or absence of 0.2 mM of the c-Met specific inhibitor PHA
(Sugen-Pfizer). Cells were then lysed according to the phospho-
protein purification kit (Qiagen Inc.), and phospho-proteins
purified according to manufacturer instructions.
Plasmids
pCMV5-Flag-LKB1
WT wild type, pCMV5-Flag-LKB1
KD ki-
nase dead, pCMV5-Flag-LKB1
S431A mutant and pCMV5-Flag-
LKB1
S431D mutant were obtained from Dario Alessi (University of
Dundee). pEBG-2t-GST-AMPKa was a kind gift from Jose ´
Miguel Lizcano and Jose ´ Manuel Lo ´pez Blanco (Autonomous
University of Barcelona). pLPCX-myc-BRAF
V600E, was subcloned
from pEB- myc-BRAF
V600E (obtained from Richard Marais,
ICRF).
Cell transfection
293T cells were seeded at 60% confluence the day before
transfection. Cells were transiently transfected with Lipofectamine
Figure 6. A model of the metabolic stress response regulation by oncogenic BRAF in melanoma cells. Resistance to stress conditions is
essential for melanoma cells survival. We propose that oncogenic BRAF
V600E signaling (left panel) protects to apoptosis by regulating BH3-family
members and confers resistance to low energy conditions promoting the uncoupling of LKB1 and AMPK through Erk1/2 and p90
Rsk. Under this
condition BRAF mutant cells have a limited response to low energy conditions. On the right panel the inhibition of BRAF signaling allows the
formation of the LKB1-AMPK complexes restoring the energy stress pathway and promoting the down-regulation of anti-apoptotic proteins such as
Mcl1. The activation of AMPK by metabolic stress conditions and the inhibition of BRAF signaling would have synergistic effects promoting apoptosis.
doi:10.1371/journal.pone.0004771.g006
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Cells were treated and lysed 36–48 h after transfection.
siRNA transfection experiments
Scramble siRNA, human BRAF siRNA On target-smartpool,
and human siRNA AMPKa1 and AMPKa2 On-target-smart-
pools were purchased from Dharmacon. 100 nM siRNA was
transfected into cells using Lipofectamine 2000 (Invitrogen Inc.)
following manufacturer protocol. Experiments were performed
72 hours after transfection.
Reagents and Western Blot analysis
PHA c-Met specific inhibitor (Pfizer) was diluted in DMSO and
used at the concentrations indicated. Mek1/2 inhibitor U0126 and
PI3K inhibitor LY294002 (Cell Signaling) were used at 10 mM
concentration. P90RSK inhibitor BI-D1870 was purchased from
MSI/WTB University of Dundee and used at 10 mM. Cells were
treated with the inhibitors for 2 hours under serum starvation and
then treated with HGF (40 ng/ml) for 10 min. Five mg of phospho-
proteins or 50 mg of total protein lysates were separated by SDS-
PAGE and transferred to a PVDF membrane (Millipore). The
membranes were blocked in 5% milk (Santa Cruz) and blotted
against different primary antibodies. ERK2 and LKB1 were from
Santa Cruz. Anti-DYKDDDDK (Flag), phospho-Erk1/2 (Thr202/
Tyr204), Erk1/2, phospho-ACC (Ser79), p-90
RSK (Thr359/
Ser363), AMPKa, p-AMPK (Thr172), phospho-S6 ribosomal
protein (Ser235/236); phosho-Bad (Ser112), anti-Bad and Bim
were purchased from Cell Signaling. Additionally p-Bad (Ser112)
was purchased from Genscript Co., Anti-GST polyclonal antibody
and anti-Flag was purchased from Sigma-Aldrich and Genscript
Co. and GAPDH was purchased from Trevigen. Mcl-1 antibody
was from DAKO. Anti-Flag resin was obtained from Sigma-Aldrich
and glutathione-resin was purchased from Amersham and Gen-
script Co. Membranes were developed using horseradish linked
secondary antibodies (GE Healthcare) and ECL (GE Healthcare).
Immunoprecipitations
36–48 h after transfection cells were treated as needed and lysed
in RIPA Buffer containing a protease cocktail II inhibitor (Sigma-
Aldrich). 800–1000 mg of total protein was subjected to immuno-
precipitation with 30 ml Flag-resin or 30 ml of Glutathion-resin.
Then, samples were washed three times with RIPA buffer and
SDS-loading sample buffer was added to the samples. Samples
were separated by SDS-PAGE.
Cell viability and apoptosis assays
Cell viability and dead cells were counted by using Guava
ViaCount reagent (Gevara Technologies) cell counter (ViaCount).
Apoptosis was measured using the Annexin V-EGFP apoptosis
detection kit (Genscript corporation) following the manufacturer’s
protocol. Positive cells for Annexin V-EGFP and propidium iodide
staining were analyzed and quantified by flow cytometry
(FACScalibur).
Image analysis
Bands from tumor samples were quantified using NIH1.6 Image
software. Normalization of p-proteins was performed against the
normalized amount of the total phosphorylated protein. Other
proteins were normalized against GAPDH.
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